Document:

DELTATHREE,
INC.

     

    2009
STOCK INCENTIVE PLAN

    

    RESTRICTED STOCK
AWARD

    102
CAPITAL GAINS TRACK GRANT

    UNDER
SECTION 102(B)(2) OF THE ISRAELI INCOME TAX ORDINANCE

     

    This
RESTRICTED STOCK AWARD AGREEMENT (the “Agreement”), dated as
of _________________ (the “Grant Date”), is delivered
by deltathree, Inc. (the “Company”) to
_______________ (the “Participant”).  Capitalized
terms used herein and not otherwise defined herein have the meaning given to
them in the Plan (as defined below).

     

    WHEREAS,
the Company maintains the deltathree, Inc. 2009 Stock Incentive Plan including
Appendix A – Israeli Participants thereto (the “Plan”) for the
benefit of its and its Affiliates’ employees, directors, and
consultants;

     

    NOW,
THEREFORE, in consideration of the covenants and agreements contained herein,
the parties to this Agreement, intending to be legally bound, hereby agree as
follows:

     

    1.           Grant of Restricted
Stock.  Subject to the terms and conditions set forth in this
Agreement and in the Plan, the Company hereby grants an aggregate of ___________
shares of Stock (the “Shares”) for the benefit of the
Participant.  The Shares will be registered in the name of
[__________] (the “Trustee”), who will serve as the trustee pursuant to the
Trust Agreement entered into between the Company and the Trustee (the “Trust
Agreement”), to the extent required by law to qualify under Section 102 for the
benefit of the Participant.  Participant shall be required to comply
with the ITO, the Rules, and the terms and conditions of the Trust Agreement.
The Trustee will hold the Shares for the Required Holding Period, as set forth
in Appendix A to the Plan.  The Participant hereby undertakes to
release the Trustee from any liability in respect of any action or decision duly
taken by the Trustee (except for any such actions or decisions taken in gross
negligence or willful misconduct) in relation to the Plan or any share of Stock
granted to him thereunder. The Participant hereby
confirms that he shall execute any and all documents which the Company or the
Trustee may reasonably determine to be necessary in order to comply with the ITO
and the Rules. All Shares issued hereunder will be deemed issued to the
Participant as fully paid and nonassessable shares.  The Company shall
pay any applicable stock transfer taxes imposed upon the issuance of the Shares
to the Participant hereunder.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    2.           Vesting of
Shares.   Subject to the provisions of this Agreement and
the Participant’s continuous Service to the Company or its Affiliates, the
Shares shall vest in accordance with the following schedule:

     

    
      
        
          
            
              
                
                  	
                          Date

                        	 	
                          Number of Shares Vested

                        	 
	 
      	 	 	 
	
                          First
      anniversary of the Grant Date

                        	 	 	25	%
	 
      	 	 	 	 
	
                          Second
      anniversary of the Grant Date

                        	 	 	25	%
	 
      	 	 	 	 
	
                          Third
      anniversary of the Grant Date

                        	 	 	25	%
	 
      	 	 	 	 
	
                          Fourth
      anniversary of the Grant Date

                        	 	 	25	%

                

              

            

          

        

      

    

     

    For
purposes of this Agreement, the term “vest” shall mean, with respect to any
Shares, that such Shares are no longer subject to forfeiture to the Company
pursuant to Section 3 below.  Shares that have not vested are deemed
“Restricted Shares.”  If the Participant would become vested in a
fraction of a Share, such Share shall not vest until the Participant becomes
vested in the entire Share.

     

    3.           Termination of Service;
Forfeiture of Shares.  Vesting shall cease upon the date of
termination of the Participant’s Service for any reason, including death or
Disability.  Any unvested Restricted Shares held by or on behalf of
the Participant at the time of such termination of Service shall immediately be
forfeited and deemed reconveyed to the Company, and the Company shall thereafter
be the legal and beneficial owner of the Restricted Shares and shall have all
rights and interest in or related thereto without further action by the
Participant.

     

    4.           Escrow of Stock; Rights as
Stockholder.

     

    (a)     
    At the sole discretion of the Committee, and subject to
the terms of this Section 4, the Shares may be issued in either (i) certificated
form, or (ii) uncertificated form, with the Shares recorded in the name of the
Trustee for the benefit of the Participant in the books and records of the
Company’s transfer agent with appropriate notations to the extent that the
Shares remain subject to the restrictions set forth in this
Agreement.

     

    (b)   
      For purposes of facilitating the enforcement
of the provisions of this Agreement, the Participant agrees, if so requested by
the Company, immediately upon receipt of any certificate(s) for the Restricted
Shares or deposit with the Trustee, to deliver such certificate(s), together
with an assignment separate from certificate, executed in blank by the
Participant and the Participant’s spouse (if required for transfer) with respect
to each such stock certificate, to the Secretary or Assistant Secretary of the
Company, or their designee, to hold in escrow for so long as such Restricted
Shares have not vested pursuant to the vesting schedule set forth in Section 2,
with the authority to take all such actions and to effectuate all such transfers
and/or releases as may be necessary or appropriate to accomplish the objectives
of this Agreement in accordance with the terms hereof.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

     

    (c)          The
Participant hereby acknowledges that the appointment of the Secretary or
Assistant Secretary of the Company (or their designee, including the Trustee) as
escrow holder hereunder with the stated authorities is a material inducement to
the Company to make this Agreement and that such appointment is coupled with an
interest and is accordingly irrevocable.  The Participant agrees that
if the Restricted Shares are held electronically in a book entry system
maintained by the Company’s transfer agent or other third party, the terms and
conditions of this Section 4 applicable to certificated Restricted Shares will
apply with the same force and effect to such electronic method for holding the
Restricted Shares.  The Participant agrees that such escrow holder
shall not be liable to any party hereto (or to any other party) for any actions
or omissions unless such escrow holder is grossly negligent relative
thereto.  The escrow holder may rely upon any letter, notice or other
document executed by any signature purported to be genuine and may resign at any
time.

     

    (d)          Certificates
representing Shares issued pursuant to this Agreement shall, until all
restrictions on transfer imposed pursuant to this Agreement lapse or shall have
been removed and new certificates are issued, bear the following legend (or such
other similar or additional legends as shall be determined by the
Committee):

     

    “THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN VESTING
REQUIREMENTS AND MAY BE SUBJECT TO FORFEITURE UNDER THE TERMS OF THAT CERTAIN
RESTRICTED STOCK AWARD AGREEMENT BY AND BETWEEN DELTATHREE, INC. AND THE
REGISTERED OWNER OF SUCH SHARES, AND SUCH SHARES MAY NOT BE, DIRECTLY OR
INDIRECTLY, OFFERED, TRANSFERRED, SOLD, ASSIGNED, PLEDGED, HYPOTHECATED OR
OTHERWISE DISPOSED OF UNDER ANY CIRCUMSTANCES, EXCEPT PURSUANT TO THE PROVISIONS
OF SUCH AGREEMENT.”

     

    (e)          Except
as otherwise provided herein and subject to the restrictions contained herein,
the Participant shall have all the rights of a stockholder with respect to the
Shares, including the right to vote the Shares and the right to receive any cash
or stock dividends paid to or made with respect to the Shares, subject to the
terms of the Plan and the requirement of Section 102.

     

    5.           Change of Control or Other
Transaction.  In the event of a Transaction (as defined in the
Plan), there will not be any acceleration of vesting or release of restrictions
with respect to the Restricted Shares unless otherwise determined by the
Committee.  The provisions of the Plan applicable to a Transaction or
a Change of Control (each as defined in the Plan) shall apply to the Shares,
and, in the event of a Transaction or Change of Control, the Committee may take
such actions as it deems appropriate pursuant to the Plan.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

     

    6.           Taxes.

     

    (a)          The
Company, its affiliates or the Trustee will withhold a portion of the Shares
that have an aggregate market value sufficient to pay the minimum federal, state
and local income, employment and any other applicable taxes required to be
withheld with respect to the Shares.  No fractional Shares will be
withheld or issued pursuant to the grant of the Shares; unless determined
otherwise by the Company, any additional withholding necessary in lieu of such
fractional shares will be effected by the Company, its affiliates or the Trustee
through a deduction in the Participant’s paycheck or through direct payment by
the Participant to the Company in the form of cash, check or other cash
equivalent.  In lieu of withholding any Shares the Company, its
affiliates and/or the Trustee may, in its discretion, require the Participant to
pay an amount necessary to pay the applicable taxes directly to the Company in
the form of cash, check or other cash equivalent, and/or may withhold an amount
necessary to pay the applicable taxes from the Participant’s
paycheck.  In the event the withholding requirements are not satisfied
through the withholding of Shares (or, through the Participant’s paycheck or
direct payment, as indicated above), no Restricted Shares will be granted or
released to the Participant (or his or her estate) unless and until satisfactory
arrangements (as determined by the Committee) have been made by the Participant
with respect to the payment of any income and other taxes which the Company
determines must be withheld or collected with respect to such
Shares.  In addition and to the maximum extent permitted by law, the
Company, its affiliates or the Trustee has the right to withhold without notice
from salary or other amounts payable to the Participant cash in an amount
sufficient to satisfy any tax withholding obligations that cannot be satisfied
through the withholding of otherwise deliverable Shares. By accepting the Award,
the Participant expressly consents to the withholding of Shares and to any cash
or Share withholding as provided for in this Section 6.  All income
and other taxes related to the Shares are the sole responsibility of the
Participant.

     

    (b)          To
the extent applicable, this Agreement and the Award are intended to be exempt
from the provisions of Section 409A of the Code and Department of Treasury
regulations and other interpretive guidance issued thereunder, as providing for
the transfer of restricted property as described in Section 1.409A-l(b)(6) of
the Department of Treasury regulations. Notwithstanding any provision of this
Agreement to the contrary, in the event that the Committee determines that the
Award may be subject to Section 409A of the Code, the Committee may adopt such
amendments to this Agreement or adopt other policies and procedures (including
amendments, policies and procedures with retroactive effect), or take any other
actions, that the Committee determines are necessary or appropriate to (i)
exempt the Award from Section 409A of the Code and/or preserve the intended tax
treatment of the benefits provided with respect to the Award, or (ii) comply
with the requirements of Section 409A of the Code and related Department of
Treasury guidance and in order to avoid the application of penalty taxes under
Section 409A of the Code.

     

    7.           Grant Subject to Plan
Provisions.  The grant of the Shares hereunder is made pursuant
to the Plan, the terms of which are incorporated herein by reference, and in all
respects shall be interpreted in accordance with the Plan.  The grant
of the Shares and this Agreement are subject to interpretations, regulations and
determinations concerning the Plan established from time to time by the
Committee in accordance with the provisions of the Plan, including, but not
limited to, provisions pertaining to (i) rights and obligations with respect to
withholding taxes, (ii) the registration, qualification or listing of the shares
of Stock, (iii) changes in capitalization of the Company, and (iv) other
requirements of applicable law.  The Committee shall have the
authority to interpret and construe this Agreement pursuant to the terms of the
Plan, and its decisions shall be conclusive as to any questions arising
hereunder.  By accepting this grant, the Participant agrees to be
bound by the terms of the Plan and this Agreement and that all decisions and
determinations of the Committee with respect to the Agreement shall be final and
binding on the Participant and the Participant’s beneficiaries.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

     

    8.           Restrictions on Sale or
Transfer of Shares.

     

    (a)          Except
as otherwise provided in the Plan, prior to the date that the Shares become
vested pursuant to the vesting schedule set forth in Section 2 and subject to
the restrictions and requirements of Section 102, the Shares shall not be
transferable, and neither the Shares nor any interest therein may be sold,
transferred, pledged, assigned, or otherwise alienated or hypothecated, other
than by will or by the laws of descent and distribution.  Any attempt
to transfer Shares in violation of this Section 8 will be null and void and will
be disregarded.

     

    (b)          In
order to ensure compliance with the restrictions on transfer set forth in this
Agreement or the Plan, the Company may issue appropriate “stop transfer”
instructions to its transfer agent, if any, and, if the Company transfers its
own securities, it may make appropriate notations to the same effect in its own
records.  The Company shall not be required (i) to transfer on its
books any Shares that have been sold or otherwise transferred in violation of
any of the provisions of this Agreement or (ii) to treat as owner of such Shares
or to accord the right to vote or pay dividends to any purchaser or other
transferee to whom such Shares shall have been so transferred.  The
Participant understands and agrees that the Company shall cause legends
reflecting the restrictions set forth in this Agreement to be placed upon any
certificate(s) evidencing ownership of the Shares together with any other
legends that may be required by the Company or under the Securities Act or the
laws of any applicable state or other jurisdiction.

     

    (c)          As
a condition to receive the Shares, the Participant agrees to be bound by the
Company’s policies regarding the limitations on the transfer of the Shares, and
understands that there may be certain times during the year that the Participant
will be prohibited from selling, transferring, pledging, donating, assigning,
mortgaging, hypothecating or otherwise encumbering the Shares.

     

    9.           No Employment or Other
Rights.  The grant of the Shares shall not confer upon the
Participant any right to be retained in the Service of the Company or any
Affiliate and shall not interfere in any way with the right of the Company or
the applicable Affiliate to terminate the Participant’s Service at any
time.  The right of the Company and any applicable Affiliate to
terminate at will the Participant’s Service at any time for any reason is
specifically reserved.

     

    10.           Assignment and
Transfers.  The rights and protections of the Company hereunder
shall extend to any successors or assigns of the Company and to any
Affiliate.  This Agreement may be assigned by the Company without the
Participant’s consent.

     

    11.           Effect on Other
Benefits.  The value of Shares granted hereunder shall not be
considered eligible earnings for purposes of any other plans maintained by the
Company or any other Affiliate, and such value shall not be considered part of
the Participant’s compensation for purposes of determining or calculating other
benefits that are based on compensation, such as life
insurance.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

    12.           Applicable
Law.  The validity, construction, interpretation and effect of
this instrument shall be governed by and construed in accordance with the laws
of the State of Delaware, without giving effect to the conflicts of laws
provisions thereof.

     

    13.           Notice.  Any
notice to the Company provided for in this instrument shall be addressed to the
Company in care of the Board, Attn: General Counsel at the Company’s corporate
headquarters, and any notice to the Participant shall be addressed to such
Participant at the current address shown on the payroll records of the Company
or the applicable Affiliate, or to such other address as the Participant may
designate to the Company or the applicable Affiliate in writing.  Any
notice shall be delivered by hand, sent by facsimile or enclosed in a properly
sealed envelope addressed as stated above, registered and deposited, postage
prepaid, in a post office regularly maintained by the United States Postal
Service.

     

    14.           Counterparts.  This
Agreement may be executed in one or more counterparts, each of which shall be
deemed an original but both of which together shall constitute one and the same
instrument.

     

    [SIGNATURE PAGE
FOLLOWS]

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    IN
WITNESS WHEREOF, the Company has caused its duly authorized officers to execute
and attest this Agreement, and the Participant has executed this Agreement,
effective as of the Grant Date.

    

    
      
        
          
            
              
                	
                        DELTATHREE,
      INC.

                      
	 
      	 
      
	
                        By:

                      	 
      
	
                        Name:

                      	 
      
	
                        Title:

                      	 
      

              

            

          

        

      

    

     

    I hereby
accept the grant of the Shares described in this Agreement, and I agree to be
bound by the terms of the Plan and this Agreement, as well as Section 102 and
the Rules promulgated in connection therewith, and the Trust Agreement.
Furthermore, I agree that the Shares will be issued to and in the name of the
Trustee to hold on my behalf, pursuant to the terms of the ITO, the Rules and
the Trust Agreement.  In addition, I confirm that I am familiar with
the terms and provisions of Section 102, particularly the Capital Gains Track
described in subsection (b)(2) thereof, and agree that I will not require the
Trustee to release to me or to sell the Shares to a third party, during the
Restricted Holding Period, unless permitted to do so by applicable law. I hereby
further agree that all of the decisions and determinations of the Committee
shall be final and binding.

    

    
      
        
          
            
              	
                      Participant:

                    	 
      

            

          

        

      

    

    
      
        
          
            	
                    Date:

                  	 
      

          

        

      

    

     

    
      
         

      

      
        7Unassociated Document

    
      
        Exhibit
10.1

      

      
        

      

      
        AGREEMENT ON ASSIGNMENT AND
COMPENSATION FOR INVENTIONS

      

      
         

        THIS
AGREEMENT, effective July 2, 2008, is by
and between The Quigley Corporation, a corporation of the State of Pennsylvania,
having a principal place of business at Kells Building, 621 Shady Retreat Road,
Doylestown, Pennsylvania 18901-1349, United States of America, (hereinafter
"Quigley") and Dr. Richard Rosenbloom, a citizen of the United States of
America, residing at 1416 Tanglewood Drive, North Wales, Pennsylvania, 19454,
United States of America (hereinafter "Dr. Rosenbloom").

      

      
         

        WHEREAS
Dr. Rosenbloom had certain concepts and/or inventions prior to the date of him
becoming an employee of The Quigley Corporation.

      

      
         

        WHEREAS
Quigley desires to obtain entire right, title and interest in and to the
Rosenbloom concepts and/or inventions and to pursue such concepts and/or
inventions through investment and the work of Dr. Rosenbloom, and in and to any
patent applications and patents relating to the subject matter of such concepts
and/or inventions in any and all countries.

      

      
         

        WHEREAS
Dr. Rosenbloom assigned the entire right, title and interest in and to said
concepts and/or inventions, and in and to any patent applications and patents
relating to the subject matter of said inventions in any and all countries by
virtue of executed assignment documents.

      

      
         

        WHEREAS
Quigley agreed to compensate Dr. Rosenbloom for assigning the entire right,
title and interest into Dr. Rosenbloom's concepts and/or inventions made prior
to the date he became an employee of Quigley.

      

      
         

        WHEREAS
Quigley has made a substantial investment of capital, labor and other resources
into the development of the concepts and/or inventions made by Dr. Rosenbloom
while an employee of Quigley, as well as patenting the inventions during the
period of his employment by Quigley.

      

      
         

        THEREFORE,
the parties agree as follows:

      

      
         

        ARTICLE I
- DEFINITIONS

      

      
         

        
          	
                  1.0

                	
                  Quigley
      and Dr. Rosenbloom are hereunder commonly reviewed to as "parties" (in
      singular and plural usage, as required by the
  context.

                

        

      

      
         

        
          	
                  1.1

                	
                  Terms
      in this agreement (other than the name of the parties and Article
      headings) which are set forth in upper case letters have the meanings
      established for such terms in the succeeding paragraphs of this ARTICLE
      I.

                

        

      

      
         

        
          	
                  1.2

                	
                  INVENTIONS
      made by Dr. Rosenbloom prior to or after the date of his employment by Quigley, which are
      specifically set forth in Exhibit A
  hereto.

                

        

      

      
        

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

         

        
          
          

        

      

      
        
          	
                  1.3

                	
                  PATENTS
      means the patents listed in Exhibit A hereto, as well as any
      patent granted on the basis of any patent application listed in
      Exhibit A hereto, or which claims priority to any patent application
      listed in Exhibit A hereto under the relevant provisions of the Paris
      Convention, as well as reexaminations and reissues thereof which may
      be granted upon said application and upon any and all continuation or
      divisional applications for patents for said inventions, in and
      for the United States and foreign
  countries.

                

        

      

      
         

        
          	
                  1.4

                	
                  ROYALTY-BEARING
      PRODUCT means any product which embodies one or more of the
      INVENTIONS and comes within the scope of any unexpired claim of any
      of the PATENTS.

                

        

      

      
         

        
          	
                  1.5

                	
                  LICENSING
      COSTS means costs incurred by Quigley to obtain any licenses from
      third parties necessary to make, use, sell or offer to sell
      ROYALTY- BEARING
PRODUCTS.

                

        

      

      
         

        
          	
                  1.6

                	
                  TITLE
      DEFENSE COSTS means costs incurred by Quigley to defend its title
      to the INVENTIONS, any patent applications for protection of the
      INVENTIONS, and/or any PATENTS from any challenge to Quigley's title
      made by a third party.

                

        

      

      
         

        
          	
                  1.7

                	
                  NET
      SALES, according to Generally Accepted Accounting Principles
      (GAAP), in respect to ROYALTY-BEARING PRODUCTS sold means amounts
      actually collected after deduction of certain items, such as, but is
      not limited to, regular trade and quantity discounts, returns and
      allowances, co-operative incentives, less LICENSING COSTS and TITLE
      DEFENSE COSTS.

                

        

      

      
         

        ARTICLE
II - REPRESENTATIONS, WARRANTIES AND LIMITATIONS

      

      
         

        
          	
                  2.1       

                	
                  Dr.
      Rosenbloom represents and warrants in respect to the PATENTS that Dr.
      Rosenbloom has the legal right to extend the rights granted to Quigley in
      this agreement and in the assignment agreements, which agreements are
      incorporated by reference, and that Dr. Rosenbloom has not made and will
      not make any commitments to others inconsistent with or in derogation of
      such rights.

                

        

      

      
         

        
          	
                  
                    2.2

                  

                	
                  Dr.
      Rosenbloom represents and warrants that Dr. Rosenbloom has not published,
      caused to be published, publicly used or disclosed, caused to be publicly
      used or disclosed, offered for sale or caused to be offered for sale, any
      of the INVENTIONS prior to the date of filing of the first United States
      patent application which discloses the respective one of the
      INVENTIONS.

                

        

      

      
         

        
          	
                  2.3

                	
                  Dr.
      Rosenbloom represents and warrants that he is the original, first and
      sole inventor of each of the
INVENTIONS.

                

        

      

      
         

        
          	
                  2.4

                	
                  Dr.
      Rosenbloom represents and warrants that he has disclosed to Quigley
      all information in his possession
      pertaining to the INVENTIONS which may be necessary or useful
      for the preparation and filing of patent applications for the protection of such INVENTIONS,
      which may be required for the patent applicant to satisfy its duty of disclosure
      to any of the patent offices in which a patent application for protection of any
      of said INVENTIONS is filed, and which may be required to determine ownership of said INVENTIONS
      under the applicable
law.

                

        

      

      
        

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

         

        
          	
                  2.5

                	
                  Dr.
      Rosenbloom represents and warrants that he has been advised of his right
      to have this agreement reviewed by independent counsel of his own
      choosing and that he has, in fact, had this agreement reviewed by
      independent counsel or has freely chosen to waive this
      right.

                

        

      

      
         

        
          	
                  2.6

                	
                  Dr.
      Rosenbloom represents and warrants that he has not relied on
      any representations made by counsel for Quigley in entering into this
      agreement.

                
	 	 
	
                  2.7

                	Nothing
      in this agreement shall be construed as:
	 	 
	 	(a) 
      A
      requirement that either party shall file any patent application(s), secure
      any patent(s), or maintain any patent(s) in
force,
	 	 
	 	(b) 
      An
      obligation to bring or prosecute actions or suits against third parties
      for infringement of any patent, or
	 	 
	 	(c) 
      Granting
      by implication, estoppel or otherwise, any licenses or rights
      under any patents other than
PATENTS.

        

      

      
         

        ARTICLE
III - FILING AND PROSECUTION OF APPLICATIONS

      

      
         

        
          	
                  3.1

                	
                  Dr.
      Rosenbloom shall, from time to time, on request, supply such
      additional information as may be necessary or desirable to facilitate
      prosecution of patent applications for the protection of the
      INVENTIONS.

                

        

      

      
         

        
          	
                  3.2

                	
                  Dr.
      Rosenbloom shall, each time a request is made and without undue
      delay, execute and deliver such papers as may be necessary or
      desirable to perfect the title to the INVENTIONS, and any patent
      applications or PATENTS to Quigley, its successors, assigns, nominees
      or legal representatives.

                

        

      

      
         

        
          	
                  3.3

                	
                  Dr.
      Rosenbloom shall testify in any legal proceedings, sign all lawful
      papers, execute all disclaimers and divisional, continuing, reissue
      and foreign applications, make all rightful oaths, and generally do
      everything possible to aid Quigley, its successors, assigns, nominees
      or legal representatives, to obtain and enforce, for its or their own
      benefit, proper patent protection for the INVENTIONS in any and all
      countries.

                
	 	 
	
                  3.4

                	Quigley
      will accept financial responsibility
for:

        

      

      
         

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      
        
          	
                  (a)   

                	
                  Preparation,
      by a patent lawyer in independent practice who shall be nominated by
      Quigley, of a patent application or applications on
      patentable aspects of the
INVENTIONS,

                

        

      

      
        
          
            	
                    (b)   

                  	
                    Filing,
      upon execution by Dr. Rosenbloom, of such patent application
      or applications, and

                  
	
                    (c)   

                  	
                    Prosecution
      by such nominated lawyer of the application or
    applications.

                  

          

        

      

      
                    

      

      
        
          	
                  3.5

                	
                  Quigley
      may, at any time, decide not to file a patent application, decide not to
      further prosecute a patent application, or decide not to maintain a
      patent, at its own
discretion.

                

        

      

      
         

        ARTICLE
IV - ASSIGNMENT OF RIGHTS

      

      
         

        
          	
                  4.1

                	
                  Dr.
      Rosenbloom shall assign all right, title and interest in and to
      said INVENTIONS, and in and to any patent applications for protection
      of said INVENTIONS, including the right to claim priority to the
      patent applications in any foreign patent application entitled to
      claim such priority under national law, international conventions,
      treaties or otherwise, and any and all continuations, divisions, and
      renewals of, and substitutes for, said applications, and in, to
      and under any and all patents which may be granted on or as a result
      of said patent applications in any and all countries, and any reissue
      or reissues, or extension or extensions of said patents, and
      authorize Quigley to file in Dr. Rosenbloom's name, applications for
      patents in all countries, the same to be held and enjoyed by Quigley,
      its successors, assigns, nominees or legal representatives, to the full
      end of the term or terms for which said patents, respectively, may be
      granted, reissued or extended, as fully and entirely as the same
      would have been held and enjoyed by me had this assignment, sale and
      transfer not been made.

                

        

      

      
         

        
          	
                  4.2

                	
                  Quigley
      shall have the right to bring suit in its own name, or, if required by
      law, jointly with Dr. Rosenbloom, at its own expense and on its own
      behalf, for infringement of the PATENTS. In any such suit, Quigley
      shall have the right to enjoin for infringement and to collect for
      its use, damages, profits, and awards of whatever nature recoverable
      for such infringement, and to settle any claim or suit for infringement of
      the PATENTS by granting the infringing party a license under one or
      more of the PATENTS. Quigley shall pay to Dr. Rosenbloom five
      percent (5%) of the excess of any recoveries over expenses in such
      suits.

                

        

      

      
         

        ARTICLE V
- COMPENSATION AND REPORTS

      

      
         

        
          	
                  5.1

                	
                  In
      consideration of, and as full compensation for, the covenants made in
      this agreement, Quigley shall pay to Dr. Rosenbloom compensation in
      the amount of five percent (5%) of NET SALES, of ROYALTY-BEARING
      PRODUCTS.

                

        

      

      
         

        
          	
                  5.2

                	
                  Quigley
      shall pay compensation to Dr. Rosenbloom biannually, and shall
      have thirty (30) days from the end of each six-month compensation
      period to pay the compensation to Dr. Rosenbloom and provide the
      report specified in paragraph 5.4 of this agreement. As long as Dr.
      Rosenbloom is an employee of The Quigley Corporation, The Quigley
      Corporation shall withhold all applicable and appropriate federal, state
      and local taxes.

                

        

      

      
         

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

        
          
          

        

      

      
         

      

      
        
          
            	
                    5.3

                  	
                    Quigley
      shall pay to Dr. Rosenbloom five percent (5%) of any
      Royalty-Bearing License other than a license to a joint venture or a
      partnership. Quigley shall have the sole discretion to determine the
      terms of the license. If a Royalty-Bearing License is sold by The
      Quigley Corporation and consideration paid to Dr. Rosenbloom under
      this paragraph, there shall be no further obligation to pay royalties
      under Article V.

                  

          

        

      

      
         

        
          	
                  5.4

                	
                  Quigley
      shall provide a report to Dr. Rosenbloom, along with the
      compensation set forth in paragraph 5.1 above, which includes
      sufficient information to verify the correctness of the amount of
      compensation provided to Dr. Rosenbloom for the previous six-month
      period.

                

        

      

      
         

        
          	
                  5.5

                	
                  Dr.
      Rosenbloom shall have the right at his expense to audit annually the
      books and records relating to the computation of this consideration
      paid to him under this
article.

                

        

      

      
         

        ARTICLE
VI - TRANSFER OF RIGHTS AND OBLIGATIONS

      

      
         

        
          	
                  6.1

                	
                  The
      rights and obligations of Quigley under this agreement shall pass to
      any assigns for the benefit of creditors of Quigley, and to any
      receiver of Quigley's assets, or to any person or corporation
      succeeding to Quigley's entire business as a result of sale,
      consolidation, reorganization or otherwise, provided such assignee,
      receiver, person or legal entity shall, without delay, accept in writing
      the provisions of this agreement, and agree in all respects to be
      bound thereby in the place and stead of
  Quigley.

                

        

      

      
         

        
          	
                  6.2

                	
                  Quigley
      may assign the rights and obligations to any person or legal
      entity, provided such assignee, receiver, person or legal entity
      shall, without delay, accept in writing the provisions of this
      agreement, and agree in all respects to be bound thereby in the place
      and stead of Quigley.

                

        

      

      
         

        ARTICLE
VII - TERM AND TERMINATION

      

      
         

        
          	
                  7.1

                	
                  This
      agreement may only be terminated in the event of a material breach by
      either party in the due observance or performance of any covenant,
      condition or limitation of this agreement, but only if such material
      breach has not been remedied within thirty (30) days after receipt
      from the non-breaching party of written notice of such material
      breach.

                

        

      

      
         

        
          	
                  7.2

                	
                  If,
      in any proceeding in which the validity, infringement, ownership or
      priority of invention of any claim of any PATENT is in issue, a
      judgment or decree is entered which becomes not further renewable
      through the exhaustion of all

                

        

      

      
        

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

         

        
          
          

        

      

      
        permissible
applications for rehearing or review by a superior tribunal, or through the
expiration of the time permitted for such applications (hereinafter referred to
as "an irrevocable judgment"), the construction placed upon any such claim by
such irrevocable judgment shall thereafter be followed, not only as to such
claims but as to all claims to which such construction applies, with respect to
acts occurring thereafter, and, if such irrevocable judgment holds any claim
invalid or is adverse to the patent as to inventorship or ownership, Quigley
shall be relieved from including in its reports, products sold covered only by
such claim or by any broader claim to which such irrevocable judgment is
applicable, and from the performance of those other acts which may be required
by this agreement only because of any such claim: provided however, that if
there are two or more conflicting irrevocable judgments with respect to the same
claim, the decision of the higher tribunal shall be followed thereafter, but if
the tribunals be of equal dignity, the decision more favorable to the claim
shall be followed until the less favorable decision has been followed by the
irrevocable judgment of a tribunal of at least equal dignity. In the event of
conflicting irrevocable judgments by the same court, the latest judgment shall
control.

      

      
         

        ARTICLE
VIII - NOTICES, APPLICABLE LAW, ARBITRATION

      

      
         

        
          	
                  8.1

                	
                  Any
      notice, report or payment provided for in this agreement shall be
      deemed sufficiently given when sent by certified or registered mail
      address to the party for whom intended at the address given at the
      outset of this agreement or at such changed address as the party
      shall have specified by written
notice.

                

        

      

      
         

        
          	
                  8.2

                	
                  This
      agreement shall be construed, interpreted, and applied in accordance with
      the laws of the Commonwealth of
  Pennsylvania.

                

        

      

      
         

        
          	
                  8.3

                	
                  Any
      controversy or claim arising under or related to this agreement shall
      be settled by arbitration in accordance with the applicable
      arbitration rules of the American Arbitration Association before a
      single arbitrator selected in accordance with those rules, and
      judgment upon the award rendered by the arbitrator may be entered in
      any court having jurisdiction
thereof.

                

        

      

      
         

        ARTICLE
IX - INTEGRATION

      

      
         

        
          	
                  9.1 

                	
                  This
      instrument, and the Exhibit A hereto, contain the entire agreement between
      the parties and supersedes all preexisting oral agreements and any other
      written agreements, other than Assignment Agreements, respecting the
      subject matter of this agreement Any representation, promise, or condition
      in connection with such subject matter which is not incorporated in this
      agreement shall not be binding upon either party. No modification,
      renewal, extension, waiver, or termination shall be binding upon the party
      against whom the enforcement of such modification, renewal, extension,
      waiver or termination is sought, unless made in writing and signed on
      behalf of such party.

                

        

      

      
         

         

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

        IN
WITNESS WHEREOF, each of the parties intending to be legally bound hereby has
caused this agreement to be executed and duly sealed in duplicate
originals.

         

        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      
                                        
                                          
                                            	
                                                    The
      Quigley Corporation

                                                  	 	 	 	 
	 	 	 	 	 	 
	By	/s/
      Guy J. Quigley	 	 	 	/s/
      Richard Rosenbloom
	 	Guy
      J. Quigley, President  	 	 	 	Dr.
      Richard Rosenbloom
	 	
                                                  	 	 	 	
                                                     

                                                  
	 	 	 	 	 	 
	
                                                    Attest:

                                                  	 	 	 	 
	 	 	 	 	 	 
	 	/s/ Charles Phillips	 	
                                                     

                                                  	 	 
	 	
                                                    Charles
      Phillips, Secretary

                                                  	 	 	 	 

                                          

                                        

                                      

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

        
 

      

      
 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

    

     

    
      
        
          
            
              	
                      QUIG
      REF.

                    	
                      MATTER
      NO.

                    	
                      TITLE

                    	
                      SERIAL
      NO.

                    	
                      FILE
      DATE

                    	
                      PATENT
      NO.

                    	
                      ISSUE
      DATE

                    	
                      STATUS

                    	
                      EXPIRATION

                    
	
                      QR-333

                    	
                      QUIG-1001US

                    	
                      METHOD
      AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
      NEUROPATHY

                    	
                      09/740,811

                    	
                      12/21/2000

                    	
                      6,555,573

                    	
                      4/29/2003

                    	
                      ISSUED

                    	
                      3/27/2021

                    
	
                      QR-333

                    	
                      QUIG-1001USDIV1

                    	
                      METHOD
      AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
      NEUROPATHY

                    	
                      10/369,025

                    	
                      2
      /19/2003

                    	 
      	 
      	
                      PUBLISHED

                    	
                      12/21/2020

                    
	
                      QR-333

                    	
                      QUIG-1001AU

                    	
                      METHOD
      AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
      NEUROPATHY

                    	
                      2002231095

                    	
                      12/19/2001

                    	
                      2002231095

                    	
                      11/24/2005

                    	
                      ISSUED

                    	
                      12/19/2021

                    
	
                      QR-333

                    	
                      QUIG-1001CA

                    	
                      METHOD
      AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
      NEUROPATHY

                    	
                      2,431,079

                    	
                      12/19/2001

                    	 
      	 
      	
                      PENDING

                    	
                      12/19/2021

                    
	
                      QR-333

                    	
                      QUIG-1001EP

                    	
                      METHOD
      AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
      NEUROPATHY

                    	
                      01991367.2

                    	
                      12/19/2001

                    	 
      	 
      	
                      PUBLISHED

                    	
                      12/19/2021

                    
	
                      QR-333

                    	
                      QUIG-1001IL

                    	
                      METHOD
      AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
      NEUROPATHY

                    	
                      156549

                    	
                      12/19/2001

                    	 
      	 
      	
                      PENDING

                    	
                      12/19/2021

                    
	
                      QR-333

                    	
                      QUIG-1001IN

                    	
                      METHOD
      AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
      NEUROPATHY

                    	
                      00870/DELNP/2003

                    	
                      12/19/2001

                    	 
      	 
      	
                      PENDING

                    	
                      12/19/2021

                    
	
                      QR-333

                    	
                      QUIG-1001JP

                    	
                      METHOD
      AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
      NEUROPATHY

                    	
                      2002-550919

                    	
                      12/19/2001

                    	 
      	 
      	
                      PENDING

                    	
                      12/19/2021

                    
	
                      QR-333

                    	
                      QUIG-1001MX

                    	
                      METHOD
      AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
      NEUROPATHY

                    	
                      PA/A/2003/005672

                    	
                      12/19/2001

                    	
                      236311

                    	
                      4/28/2006

                    	
                      ISSUED

                    	
                      12/19/2021

                    
	
                      QR-333

                    	
                      QUIG-1001NZ

                    	
                      METHOD
      AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
      NEUROPATHY

                    	
                      526041

                    	
                      12/19/2001

                    	
                      526041

                    	
                      5/12/2005

                    	
                      ISSUED

                    	
                      12/19/2021

                    
	
                      QR-333

                    	
                      QUIG-1001ZA

                    	
                      METHOD
      AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
      NEUROPATHY

                    	
                      2003/4247

                    	
                      12/19/2001

                    	
                      2003/4247

                    	
                      7/28/2004

                    	
                      ISSUED

                    	
                      12/19/2021

                    
	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                      QR-333

                    	
                      QUIG-1011US

                    	
                      METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                    	
                      10/288,825

                    	
                      11/6
      /2002

                    	
                      7,083,813

                    	
                      8/1/2006

                    	
                      ISSUED

                    	
                      8/4/2023

                    
	
                      QR-333

                    	
                      QUIG-1011USDIV1

                    	
                      METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                    	
                      11/165,151

                    	
                      6
      /23/2005

                    	 
      	 
      	
                      PUBLISHED

                    	
                      11/6/2022

                    
	
                      QR-333

                    	
                      QUIG-1011AU

                    	
                      METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                    	
                      2002352501

                    	
                      11/6
      /2002

                    	
                      2002352501

                    	 
      	
                      ISSUED

                    	
                      11/6/2022

                    
	
                      QR-333

                    	
                      QUIG-1011CA

                    	
                      METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                    	
                      2,470,603

                    	
                      11/6
      /2002

                    	 
      	 
      	
                      PENDING

                    	
                      11/6/2022

                    
	
                      QR-333

                    	
                      QUIG-1011EP

                    	
                      METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                    	
                      02789474.0

                    	
                      11/6
      /2002

                    	 
      	 
      	
                      PUBLISHED

                    	
                      11/6/2022

                    
	
                      QR-333

                    	
                      QUIG-1011IL

                    	
                      METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                    	
                      162505

                    	
                      11/6
      /2002

                    	 
      	 
      	
                      PENDING

                    	
                      11/6/2022

                    
	
                      QR-333

                    	
                      QUIG-1011IN

                    	
                      METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                    	
                      1683/DELNP/2004

                    	
                      11/6
      /2002

                    	 
      	 
      	
                      PENDING

                    	
                      11/6/2022

                    

               

               

              
                
                  
                  

                

                
                  
                  

                  
                    

                  

                

                
                  
                  

                

              

               

              
                	
                        QUIG
      REF.

                      	
                        MATTER
      NO.

                      	
                        TITLE

                      	
                        SERIAL
      NO.

                      	
                        FILE
      DATE

                      	
                        PATENT
      NO.

                      	
                        ISSUE
      DATE

                      	
                        STATUS

                      	
                        EXPIRATION

                      

              

              
                
                  	
                          QR-333

                        	
                          QUIG-1011JP

                        	
                          METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                        	
                          2003-554096

                        	
                          11/6
      /2002

                        	 
      	 
      	
                          PUBLISHED

                        	
                          11/6/2022

                        
	
                          QR-333

                        	
                          QUIG-1011MX

                        	
                          METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                        	
                          PA/A/2004/006039

                        	
                          11/6
      /2002

                        	 
      	 
      	
                          PENDING

                        	
                          11/6/2022

                        
	
                          QR-333

                        	
                          QUIG-1011NZ

                        	
                          METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                        	
                          533439

                        	
                          11/6
      /2002

                        	
                          533439

                        	
                          10/12/2006

                        	
                          ISSUED

                        	
                          11/6/2022

                        
	
                          QR-333

                        	
                          QUIG-1011TW

                        	
                          METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                        	
                          93102875

                        	
                          11/6
      /2002

                        	 
      	 
      	
                          PUBLISHED

                        	
                          11/6/2022

                        
	
                          QR-333

                        	
                          QUIG-1011ZA

                        	
                          METHODS
      FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
    AILMENTS

                        	
                          2004/4614

                        	
                          11/6
      /2002

                        	
                          2004/4614

                        	
                          10/28/2005

                        	
                          ISSUED

                        	
                          11/6/2022

                        
	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                          QR-334

                        	
                          QUIG-1007US

                        	
                          MEDICAL
      COMPOSITION AND METHOD OF USING IT

                        	
                          09/923,090

                        	
                          8 /6
      /2001

                        	
                          6,592,896

                        	
                          7/15/2003

                        	
                          ISSUED

                        	
                          8/6/2021

                        
	
                          QR-334

                        	
                          QUIG-1007USCIP

                        	
                          NUTRITIONAL
      SUPPLEMENTS AND METHODS OF USING IT

                        	
                          10/122,991

                        	
                          4
      /15/2002

                        	
                          6,596,313

                        	
                          7/22/2003

                        	
                          ISSUED

                        	
                          8/6/2021

                        
	
                          QR-334

                        	
                          QUIG-1007AU

                        	
                          NUTRITIONAL
      SUPPLEMENTS AND METHODS OF USING IT

                        	
                          2002332464

                        	
                          8 /6
      /2002

                        	
                          2002332464

                        	
                          2/22/2007

                        	
                          ISSUED

                        	
                          8/6/2022

                        
	
                          QR-334

                        	
                          QUIG-1007CA

                        	
                          NUTRITIONAL
      SUPPLEMENT AND METHODS OF USING IT

                        	
                          2,455,391

                        	
                          8 /6
      /2002

                        	 
      	 
      	
                          PENDING

                        	
                          8/6/2022

                        
	
                          QR-334

                        	
                          QUIG-1007CN

                        	
                          NUTRITIONAL
      SUPPLEMENTS AND METHODS OF USING SAME

                        	
                          02814148.2

                        	
                          8 /6
      /2002

                        	 
      	 
      	
                          PENDING

                        	
                          8/6/2022

                        
	
                          QR-334

                        	
                          QUIG-1007IN

                        	
                          NUTRITIONAL
      SUPPLEMENT AND METHODS OF USING IT

                        	
                          0004/MUMNP/2004

                        	
                          8 /6
      /2002

                        	 
      	 
      	
                          PENDING

                        	
                          8/6/2022

                        
	
                          QR-334

                        	
                          QUIG-1007JP

                        	
                          NUTRITIONAL
      SUPPLEMENT AND METHODS OF USING IT

                        	
                          2003-518442

                        	
                          8 /6
      /2002

                        	 
      	 
      	
                          PENDING

                        	
                          8/6/2022

                        
	
                          QR-334

                        	
                          QUIG-1007IL

                        	
                          NUTRITIONAL
      SUPPLEMENTS AND METHODS OF USING SAME

                        	
                          159357

                        	
                          8 /6
      /2002

                        	
                          159357

                        	
                          11/21/2006

                        	
                          ISSUED

                        	
                          8/6/2022

                        
	
                          QR-334

                        	
                          QUIG-1007NZ

                        	
                          NUTRITIONAL
      SUPPLEMENT AND METHODS OF USING IT

                        	
                          530187

                        	
                          8 /6
      /2002

                        	 
      	 
      	
                          PUBLISHED

                        	
                          8/6/2022

                        
	
                          QR-334

                        	
                          QUIG-1007KR

                        	
                          NUTRITIONAL
      SUPPLEMENT AND METHODS OF USING IT

                        	
                          10-2004-7001862

                        	
                          8 /6
      /2002

                        	 
      	 
      	
                          PENDING

                        	
                          8/6/2022

                        
	
                          QR-334

                        	
                          QUIG-1007ZA

                        	
                          NUTRITIONAL
      SUPPLEMENT AND METHODS OF USING IT

                        	
                          2003/9802

                        	
                          8 /6
      /2002

                        	
                          2003/9802

                        	
                          7/28/2004

                        	
                          ISSUED

                        	
                          8/6/2022

                        
	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                          QR-335

                        	
                          QUIG-1006US

                        	
                          COMPOSITION
      AND METHOD FOR REDUCING RADIATION DERMATITIS

                        	
                          09/993,003

                        	
                          11/6/2001

                        	
                          6,753,325

                        	
                          6/22/2004

                        	
                          ISSUED

                        	
                          11/6/2021

                        

                   

                   

                  
                    
                      
                      

                    

                    
                      
                      

                      
                        

                      

                    

                    
                      
                      

                    

                  

                   

                  
                    	
                            QUIG
      REF.

                          	
                            MATTER
      NO.

                          	
                            TITLE

                          	
                            SERIAL
      NO.

                          	
                            FILE
      DATE

                          	
                            PATENT
      NO.

                          	
                            ISSUE
      DATE

                          	
                            STATUS

                          	
                            EXPIRATION

                          

                  

                  
                    	
                            QR-335

                          	
                            QUIG-06USCIP4

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            10/288,761

                          	
                            11/6/2002

                          	 
      	 
      	
                            PUBLISHED

                          	
                            11/6/2021

                          
	
                            QR-335

                          	
                            QUIG-1006AU2

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            2002365155

                          	
                            11/6/2002

                          	 
      	 
      	
                            PENDING

                          	
                            11/6/2022

                          
	
                            QR-335

                          	
                            QUIG-1006CA2

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            2,465,888

                          	
                            11/6/2002

                          	 
      	 
      	
                            PENDING

                          	
                            11/6/2022

                          
	
                            QR-335

                          	
                            QUIG-1006CN2

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            02826541.6

                          	
                            11/6/2002

                          	 
      	 
      	
                            PUBLISHED

                          	
                            11/6/2022

                          
	
                            QR-335

                          	
                            QUIG-1006EP2

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            02803307.4

                          	
                            11/6/2002

                          	 
      	 
      	
                            PUBLISHED

                          	
                            11/6/2022

                          
	
                            QR-335

                          	
                            QUIG-1006HK2

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            05111253.4

                          	
                            12/8/2005

                          	 
      	 
      	
                            PUBLISHED

                          	
                            12/8/2025

                          
	
                            QR-335

                          	
                            QUIG-1006IL2

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            161775

                          	
                            11/6/2002

                          	 
      	 
      	
                            PENDING

                          	
                            11/6/2022

                          
	
                            QR-335

                          	
                            QUIG-1006IN2

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            01160/DELNP/2004

                          	
                            11/6/2002

                          	 
      	 
      	
                            PENDING

                          	
                            11/6/2022

                          
	
                            QR-335

                          	
                            QUIG-1006JP2

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            2003-552220

                          	
                            11/6/2002

                          	 
      	 
      	
                            PUBLISHED

                          	
                            11/6/2022

                          
	
                            QR-335

                          	
                            QUIG-1006MX2

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            PA/A/2004/004377

                          	
                            11/6/2002

                          	 
      	 
      	
                            PUBLISHED

                          	
                            11/6/2022

                          
	
                            QR-335

                          	
                            QUIG-1006NZ2

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            532775

                          	
                            11/6/2002

                          	 
      	 
      	
                            PUBLISHED

                          	
                            11/6/2022

                          
	
                            QR-335

                          	
                            QUIG-1006ZA2

                          	
                            TOPICAL
      COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
      RADIATION

                          	
                            2004/3365

                          	
                            11/6/2002

                          	
                            2004/3365

                          	
                            5/31/2006

                          	
                            ISSUED

                          	
                            11/6/2022

                          
	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                            QR-336

                          	
                            QUIG-1006USCIP

                          	
                            COMPOSITION
      FOR RADIATION DERMATITIS AND EXPOSURE

                          	
                            10/045,790

                          	
                            1/14/2002

                          	 
      	 
      	
                            PUBLISHED

                          	 
      
	
                            QR-336

                          	
                            QUIG-1006AU

                          	
                            NUTRITIONAL
      SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
      RADIATION INJURY

                          	
                            2002309615

                          	
                            5/1/2002

                          	 
      	 
      	
                            PENDING

                          	
                            5 /1
      /2022

                          

                     

                     

                     

                    
                      
                        
                        

                      

                      
                        
                        

                        
                          

                        

                      

                      
                        
                        

                      

                    

                     

                    
                      	
                              QUIG
      REF.

                            	
                              MATTER
      NO.

                            	
                              TITLE

                            	
                              SERIAL
      NO.

                            	
                              FILE
      DATE

                            	
                              PATENT
      NO.

                            	
                              ISSUE
      DATE

                            	
                              STATUS

                            	
                              EXPIRATION

                            

                    

                    
                      
                        
                          
                            
                              	
                                      QR-336

                                    	
                                      QUIG-1006CA

                                    	
                                      NUTRITIONAL
      SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
      RADIATION INJURY

                                    	
                                      2,465,945

                                    	
                                      5/1/2002

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      5 /1
      /2022

                                    
	
                                      QR-336

                                    	
                                      QUIG-1006CN

                                    	
                                      NUTRITIONAL
      SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
      RADIATION INJURY

                                    	
                                      02822057.9

                                    	
                                      5 /1
      /2002

                                    	 
      	 
      	
                                      PUBLISHED

                                    	
                                      5 /1
      /2022

                                    
	
                                      QR-336

                                    	
                                      QUIG-1006EP

                                    	
                                      NUTRITIONAL
      SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
      RADIATION INJURY

                                    	
                                      02736624.4

                                    	
                                      5 /1
      /2002

                                    	 
      	 
      	
                                      PUBLISHED

                                    	
                                      5 /1
      /2022

                                    
	
                                      QR-336

                                    	
                                      QUIG-1006IL

                                    	
                                      NUTRITIONAL
      SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
      RADIATION INJURY

                                    	
                                      161774

                                    	
                                      5 /1
      /2002

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      5 /1
      /2022

                                    
	
                                      QR-336

                                    	
                                      QUIG-1006IN

                                    	
                                      NUTRITIONAL
      SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
      RADIATION INJURY

                                    	
                                      01165/DELNP/2004

                                    	
                                      5 /1
      /2002

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      5 /1
      /2022

                                    
	
                                      QR-336

                                    	
                                      QUIG-1006JP

                                    	
                                      NUTRITIONAL
      SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
      RADIATION INJURY

                                    	
                                      2003-541744

                                    	
                                      5 /1
      /2002

                                    	 
      	 
      	
                                      PUBLISHED

                                    	
                                      5 /1
      /2022

                                    
	
                                      QR-336

                                    	
                                      QUIG-1006MX

                                    	
                                      NUTRITIONAL
      SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
      RADIATION INJURY

                                    	
                                      PA/A/2004/004376

                                    	
                                      5 /1
      /2002

                                    	 
      	 
      	
                                      PUBLISHED

                                    	
                                      5 /1
      /2022

                                    
	
                                      QR-336

                                    	
                                      QUIG-1006NZ

                                    	
                                      NUTRITIONAL
      SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
      RADIATION INJURY

                                    	
                                      532774

                                    	
                                      5 /1
      /2002

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      5 /1
      /2022

                                    
	
                                      QR-336

                                    	
                                      QUIG-1006ZA

                                    	
                                      NUTRITIONAL
      SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
      RADIATION INJURY

                                    	
                                      2004/3364

                                    	
                                      5 /1
      /2002

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      5 /1
      /2022

                                    
	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                      QR-433

                                    	
                                      QUIG-07USDIV2

                                    	
                                      COMPOSITIONS
      AND METHODS FOR TREATMENT OF RHINOVIRUS

                                    	
                                      11/553,656

                                    	
                                      10/27/2006

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      8 /6
      /2021

                                    
	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                      QR-434

                                    	
                                      QUIG-07USCON4

                                    	
                                      COMPOSITIONS
      AND METHODS FOR TREATMENT OF HERPES

                                    	
                                      11/371,974

                                    	
                                      3 /9
      /2006

                                    	
                                      7,175,987

                                    	
                                      2
      /13/2007

                                    	
                                      ISSUED

                                    	
                                      11/5
      /2021

                                    
	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                      QR-435

                                    	
                                      QUIG-07USCIP2

                                    	
                                      ANTI-MICROBIAL
      COMPOSITIONS AND METHODS OF USING SAME

                                    	
                                      10/359,889

                                    	
                                      2 /6
      /2003

                                    	 
      	 
      	
                                      PUBLISHED

                                    	
                                      8 /6
      /2021

                                    
	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                      QR-440

                                    	
                                      QUIG-07USDIV1

                                    	
                                      NUTRITIONAL
      SUPPLEMENTS AND METHODS OF USING SAME

                                    	
                                      10/421,276

                                    	
                                      4
      /23/2003

                                    	
                                      6,827,945

                                    	
                                      12/7
      /2004

                                    	
                                      ISSUED

                                    	
                                      8 /6
      /2021

                                    
	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      

                               

                               

                              
                                
                                  
                                  

                                

                                
                                  
                                  

                                  
                                    

                                  

                                

                                
                                  
                                  

                                

                              

                               

                              
                                	
                                        QUIG
      REF.

                                      	
                                        MATTER
      NO.

                                      	
                                        TITLE

                                      	
                                        SERIAL
      NO.

                                      	
                                        FILE
      DATE

                                      	
                                        PATENT
      NO.

                                      	
                                        ISSUE
      DATE

                                      	
                                        STATUS

                                      	
                                        EXPIRATION

                                      

                              

                              	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-7USCIP3

                                    	
                                      COMPOSITIONS
      AND METHODS FOR REDUCING THE TRANSMISSIVITY OF ILLNESSES

                                    	
                                      11/012,764

                                    	
                                      12/14/2004

                                    	
                                      7,166,435

                                    	
                                      1
      /23/2007

                                    	
                                      ISSUED

                                    	
                                      11/5
      /2021

                                    
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007AU2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      2003256736

                                    	
                                      7
      /24/2003

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      7
      /24/2023

                                    
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007CA2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      2,495,447

                                    	
                                      7
      /24/2003

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      7
      /24/2023

                                    
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007CN2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      03818966.6

                                    	
                                      7
      /24/2003

                                    	 
      	 
      	
                                      PUBLISHED

                                    	
                                      7
      /24/2023

                                    
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007EP2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      03766897.7

                                    	
                                      7
      /24/2003

                                    	 
      	 
      	
                                      PUBLISHED

                                    	
                                      7
      /24/2023

                                    
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007HK2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      05112150.6

                                    	
                                      12/29/2005

                                    	 
      	 
      	
                                      PUBLISHED

                                    	
                                      12/29/2025

                                    
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007IL2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      166608

                                    	
                                      7
      /24/2003

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      7
      /24/2023

                                    
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007IN2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      258/DELNP/2005

                                    	
                                      7
      /24/2003

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      7
      /24/2023

                                    
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007JP2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      2004-526143

                                    	
                                      7
      /24/2003

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      7
      /24/2023

                                    

                               

                               

                              
                                
                                  
                                  

                                

                                
                                  
                                  

                                  
                                    

                                  

                                

                                
                                  
                                  

                                

                              

                               

                              
                                	
                                        QUIG
      REF.

                                      	
                                        MATTER
      NO.

                                      	
                                        TITLE

                                      	
                                        SERIAL
      NO.

                                      	
                                        FILE
      DATE

                                      	
                                        PATENT
      NO.

                                      	
                                        ISSUE
      DATE

                                      	
                                        STATUS

                                      	
                                        EXPIRATION

                                      

                              

                              	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007KR2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      2005-7002080

                                    	
                                      7
      /24/2003

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      7
      /24/2023

                                    
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007MX2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      PA/A/2005/001051

                                    	
                                      7
      /24/2003

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      7
      /24/2023

                                    
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007NZ2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      537821

                                    	
                                      7
      /24/2003

                                    	 
      	 
      	
                                      PENDING

                                    	
                                      7
      /24/2023

                                    
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-07WO3

                                    	
                                      COMPOSITIONS
      AND METHODS FOR REDUCING THE TRANSMISSIVITY OF ILLNESSES

                                    	
                                      PCT/US2005/045218

                                    	
                                      12/14/2005

                                    	 
      	 
      	
                                      PUBLISHED

                                    	 
      
	
                                      QR-433-437

                                      QR-439

                                      QR-441-441(a)

                                      QR-444

                                      QR-446

                                    	
                                      QUIG-1007ZA2

                                    	
                                      ANTI-MICROBIAL
      METHODS AND COMPOSITIONS

                                    	
                                      2005/0517

                                    	
                                      7
      /24/2003

                                    	
                                      2005/0517

                                    	
                                      12/28/2005

                                    	
                                      ISSUED

                                    	
                                      7
      /24/2023

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}]]